As Biogen hunts for a turnaround CEO, execs sketch out a hazy look at an uncertain new future
Once again, Biogen’s board of directors is looking to execute a brisk turnaround in order to satisfy investors that it has a solid footing and a clear road ahead to grow revenues again, instead of managing a shrinking revenue stream from aging products.
Longtime observers have been here before. Jim Mullen was given a sharp push out of the executive suite back in 2010, making way for George Scangos and his team to come in and manage the Tecfidera launch, which they did with great success. Michel Vounatsos was promoted from commercial chief a little more than 5 years ago as the board took the insider, stay-the-course route to find someone to manage the next generation of the pipeline and product generation.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.